ストックスクリーナーアプリを入手
15.82
1.80%
-0.29
アフターアワーズ：
15.82
Dyne Therapeutics Inc (DYN) 最新ニュース
(DYN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes - Stocktwits
Dyne Therapeutics Is Maintained at Buy by Chardan Capital - Moomoo
Dyne: Recent Price Drop On Rival's DM1 Data Creates (Risky) 'Buy The Dip' Scenario (DYN) - Seeking Alpha
Stifel reiterates Dyne Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
DYN Maintained by Chardan Capital -- Price Target Holds at $38 - GuruFocus
Cantor Fitzgerald reiterates Dyne Therapeutics stock rating By Investing.com - Investing.com Canada
Wainwright cuts Dyne Therapeutics stock price target on DM1 assumptions By Investing.com - Investing.com Canada
Chardan Capital maintains Buy rating on Dyne Therapeutics, $38 price target - TradingView
DYN Maintained by HC Wainwright & Co. -- Price Target Lowered to $32 - GuruFocus
Jefferies reiterates Dyne Therapeutics stock rating on trial data By Investing.com - Investing.com UK
Is Dyne Therapeutics (DYN) A Bargain After ACHIEVE Trial Data? - Simply Wall Street
Dyne Therapeutics stock rises on positive DM1 trial results - uk.finance.yahoo.com
After a year, Dyne trial participants showed better walking-test times and muscle strength - Stock Titan
DYN Reiterated by Piper Sandler -- Price Target Maintained at $4 - GuruFocus
Piper Sandler reiterates Dyne Therapeutics stock rating on drug approval confidence - Investing.com Canada
Raymond James Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $37 - Moomoo
Certain Stock Options of Dyne Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2026. - marketscreener.com
TLX Stock Price and Chart — NASDAQ:TLX - TradingView
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Do Dyne Therapeutics’ (DYN) Expanded DM1 Data Presentations Redefine Its Rare-Disease Investment Narrative? - Yahoo Finance
What Dyne Therapeutics Stock One Year Trial Data Means For Shareholders - simplywall.st
DYN: Strong clinical progress and launch readiness position the company for leadership in neuromuscular disease therapies - TradingView
Dyne Therapeutics, Inc. at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock - Stocktwits
Analysts Offer Insights on Healthcare Companies: Eocene (EOCN) and Dyne Therapeutics (DYN) - The Globe and Mail
Dyne Therapeutics at Cantor conference: launch plans and pipeline expand By Investing.com - Investing.com Canada
(DYN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Cuts Target Price to $36 - Moomoo
Wall Street Slashes Dyne Therapeutics Targets After Novartis DM1 Trial Failure - finance.biggo.com
DYN Maintained by Morgan Stanley -- Price Target Lowered to $36 - GuruFocus
Dyne Therapeutics Shares Plummet After Novartis Phase 3 Trial Failure - Intellectia AI
Dyne Therapeutics CMO Kerr Douglas Sells 5,035 Shares Between $18.88 and $24.35 (NASDAQ: DYN) - Kalkine Media
DYN Downgraded by JP Morgan -- Price Target Lowered to $10.00 - GuruFocus
Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says - Moomoo
DYN Maintains Rating by RBC Capital -- Price Target Lowered to $30 - GuruFocus
Dyne downgraded at J.P. Morgan on Novartis setback (DYN:NASDAQ) - Seeking Alpha
Dyne Therapeutics stock price target lowered to $30 by RBC Capital - Investing.com Canada
Dyne Therapeutics falls 16% after Novartis DM1 trial failure raises doubts on RNA therapy success - Pluang
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class (NASDAQ:DYN) - Seeking Alpha
RBC Cuts Price Target on Dyne Therapeutics to $30 From $35, Keeps Outperform, Speculative Risk - marketscreener.com
Dyne Therapeutics stock faces pressure after rival drug fails trial By Investing.com - Investing.com Nigeria
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN), NewAmsterdam Pharma Company (NAMS) and Ionis Pharmaceuticals (IONS) - theglobeandmail.com
Dyne Therapeutics (DYN) officer plans $106K stock sale - Stock Titan
Dyne Therapeutics (Nasdaq: DYN) officer to sell 3,000 shares from RSUs - Stock Titan
Dyne Therapeutics (DYN) CCO’s tax sales leave 102,966 unvested RSUs - stocktitan.net
Tax-driven stock sale by Dyne (DYN) medical chief - Stock Titan
Dyne Therapeutics (DYN) CEO sells shares to cover taxes - Stock Titan
Raymond James sets Dyne Therapeutics price targ... - Pluang
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Reuters
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling - Benzinga
Raymond James cuts Dyne Therapeutics price target on DM1 trial risk - Investing.com Nigeria
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 at Upcoming Medical Meetings - Investing News Network
Morning Market Movers: FCUV, BNC, BIAF, DYN See Big Swings - rttnews.com
Dyne Therapeutics (DYN) Shares Plunge 28% After Novartis Phase I - GuruFocus
Dyne Therapeutics (DYN) Faces Market Pressure After Novartis DM1 - GuruFocus
Dyne Therapeutics (DYN) Faces Pressure After Novartis Trial Fail - GuruFocus
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings - Yahoo Finance
Dyne Therapeutics stock faces pressure after rival drug fails trial - Investing.com
Dyne Therapeutics Shares Fall 31% Premarket With No Catalyst Confirmed - Yahoo Finance
1.48%
0.31%
大文字化:
|
ボリューム (24 時間):